{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Slattery JD"],"funding":["BLRD VA","NIDDK NIH HHS","NHLBI NIH HHS"],"pagination":["1503096"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11913664"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16"],"pubmed_abstract":["Previous studies have implicated hindbrain oxytocin (OT) receptors in the control of food intake and brown adipose tissue (BAT) thermogenesis. We recently demonstrated that hindbrain [fourth ventricle (4V)] administration of oxytocin (OT) could be used as an adjunct to drugs that directly target beta-3 adrenergic receptors (β3-AR) to elicit weight loss in diet-induced obese (DIO) rodents. What remains unclear is whether systemic OT can be used as an adjunct with the β3-AR agonist, CL 316243, to increase BAT thermogenesis and elicit weight loss in DIO rats. We hypothesized that systemic OT and β3-AR agonist (CL 316243) treatment would produce an additive effect to reduce body weight and adiposity in DIO rats by decreasing food intake and stimulating BAT thermogenesis. To test this hypothesi"],"journal":["Frontiers in endocrinology"],"pubmed_title":["Effects of systemic oxytocin and beta-3 receptor agonist (CL 316243) treatment on body weight and adiposity in male diet-induced obese rats."],"pmcid":["PMC11913664"],"funding_grant_id":["R01 HL107256","R01 DK115976","I01 BX004102","P30 DK017047","R01 HL091333"],"pubmed_authors":["Wolden-Hanson T","Slattery JD","Williams AL","Honeycutt MK","Rambousek JR","O'Brien KD","Tsui E","Graham JL","Havel PJ","Blevins JE","Goldberg M","Wietecha TA"],"additional_accession":[]},"is_claimable":false,"name":"Effects of systemic oxytocin and beta-3 receptor agonist (CL 316243) treatment on body weight and adiposity in male diet-induced obese rats.","description":"Previous studies have implicated hindbrain oxytocin (OT) receptors in the control of food intake and brown adipose tissue (BAT) thermogenesis. We recently demonstrated that hindbrain [fourth ventricle (4V)] administration of oxytocin (OT) could be used as an adjunct to drugs that directly target beta-3 adrenergic receptors (β3-AR) to elicit weight loss in diet-induced obese (DIO) rodents. What remains unclear is whether systemic OT can be used as an adjunct with the β3-AR agonist, CL 316243, to increase BAT thermogenesis and elicit weight loss in DIO rats. We hypothesized that systemic OT and β3-AR agonist (CL 316243) treatment would produce an additive effect to reduce body weight and adiposity in DIO rats by decreasing food intake and stimulating BAT thermogenesis. To test this hypothesi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-04-08T15:31:57.699Z","creation":"2025-04-22T07:21:07.815Z"},"accession":"S-EPMC11913664","cross_references":{"pubmed":["40104132"],"doi":["10.3389/fendo.2025.1503096"]}}